Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has issued an announcement.
Eupraxia Pharmaceuticals, a clinical-stage biotech specializing in locally delivered, extended-release drugs based on its Diffusphere microsphere technology, is advancing a pipeline that includes EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis pain. The company targets high unmet medical needs across pain, inflammatory gastrointestinal disease and potentially oncology and infectious disease, seeking to improve the safety and durability of existing therapies.
The company announced that its management team will engage investors at the Raymond James Biotech Innovation Symposium in New York on April 14 and at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21–22, where it will present and hold one-on-one meetings. These appearances underscore Eupraxia’s efforts to raise its profile in the capital markets, communicate progress on its clinical programs and potentially attract new institutional interest to support its development strategy.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapies using its proprietary Diffusphere polymer-based microsphere technology. The platform is designed to provide hyper-local, controlled delivery of both existing and novel drugs to improve safety, tolerability, efficacy and duration of effect, with current development focused on pain and inflammatory gastrointestinal diseases and potential applications in oncology, infectious disease and other critical areas.
The company’s pipeline includes EP-104GI, in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis using localized esophageal wall injection, and EP-104IAR, which met its primary endpoint and most secondary endpoints in a Phase 2b SPRINGBOARD trial for knee osteoarthritis pain. Eupraxia is also advancing additional long-acting formulations for other inflammatory joint indications and oncology, aiming to enhance the performance of currently approved drugs.
Average Trading Volume: 86,938
Technical Sentiment Signal: Buy
Current Market Cap: C$590.9M
For detailed information about EPRX stock, go to TipRanks’ Stock Analysis page.